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Growth
Centrosomes play a major role in mitotic-spindle organiza-
tion and cytokinesis. By serving as a scaffold for cell-cycle
regulators, they also inﬂuence cell-cycle progression indi-
rectly. New data by Rauch et al. and by Grifﬁth et al. impli-
cate a major centrosomal protein, pericentrin, in two
phenotypes associated with reduced body size and micro-
cephaly—Seckel syndrome and microcephalic osteodys-
plastic primordial dwarﬁsm type II (MOPD II)—andprovide
complementary data on the role of pericentrin in the cell.
Pericentrin is not the ﬁrst centrosomal protein to be impli-
cated in microcephaly. In fact, prior reports of mutations
that occur in centrosome genes and cause primary micro-
cephaly allowed both groups of authors to zero in on the
gene for pericentrin (PCNT) after initial homozygositymap-
ping in affected families. These results also implicate the
centrosome in body-size determination. Additional data
from Rauch et al. demonstrate that MOPD II mutations in
PCNT cause abnormal mitotic morphology in ﬁbroblasts,
low-level mosaic variegated aneuploidy, and premature
sister-chromatid separation, indicating that the cells have
a defect in a spindle-assembly checkpoint. Grifﬁth et al.
link the Seckel-syndrome-associated defects in pericentrin
to impaired ATR signaling, providing the ﬁrst demonstra-
tion that a structural protein of the centrosome is involved
in the ATR-dependent DNA-damage response.MOPD II has
been clinically distinguished from Seckel syndrome largely
on the basis of disproportionate shortening of the forearms
and grossly normal brain development such thatmost indi-
viduals with MOPD II lack serious mental retardation. The
ﬁnding that loss-of-function mutations in PCNT are found
in individuals with either diagnosis places the two disorders
on the same disease spectrum. They also suggest a central
role for the centrosome in human growth.
A. Rauch et al. (2008). Science. Published online January 3,
2008. 10.1126/science.1151174; E. Grifﬁth et al. (2007). Nat.
Genet. Published online December 23, 2007. 10.1038/
ng.1007.80.The Role of Ataxin-2 in Both SCA1 and SCA2
The spinocerebellar ataxias (SCA) are a group of disorders
that—although clinically quite similar—are geneticallyThe Amedistinct. Because of the common neuropathologies seen
with these disorders and the fact that several of them are
caused by polyglutamine expansions in different genes, it
is believed that there is some commonality to their under-
lying pathological processes. Al-Ramahi et al. now report
that a change to the localization of Ataxin-2 may be
a link between SCA1 and SCA2. These results come despite
the fact that Ataxin-1 and Ataxin-2, the proteins mutated
in SCA1 and SCA2, respectively, were not thought to be co-
localized in cells, and their only similarity is the polyglut-
amine domain. In a screen for geneticmodiﬁers of Ataxin-1
neurotoxicity in Drosophila, overexpression of Ataxin-2
was found to enhance, and underexpression to repress,
the effects of expanded Ataxin-1. Ataxin-1 and Ataxin-2
interact in vitro, but, importantly, Al-Ramahi et al. also
demonstrate that the proteins colocalize when there is
a polyglutamine expansion in Ataxin-1. This pathogenic
form of Ataxin-1 alters the localization of Ataxin-2 from
the cytoplasm to the nucleus in cell culture and in pontine
neurons from postmortem brains of SCA1 patients. The
authors conﬁrm their hunch that it is this change to the
localization of Ataxin-2 that modulates neurotoxicity
when they ﬁnd that putting a nuclear localization signal
on Ataxin-2 mimics some of the neurotoxic effects of
expanded Ataxin-1. Whether Ataxin-2 is a common link
in all of the forms of SCA remains to be seen.
I. Al-Ramahi et al. (2007). PLoS Genet. 3, 2551–2564.
10.1371/journal.pgen.0030234.A Genetic Battle of the Sexes
Imprinted genes tend to be highly expressed in the pla-
centa, and disruption of these genes often has effects on
both fetal and placental growth. In fact, the evolution of
imprinted genes has been suggested to be due to the con-
ﬂict between thematernal and paternal alleles for maternal
investment in the growth of offspring. In other words, fa-
thers might want their offspring to suck as many resources
as they can off the mother, but maximizing fetal growth
and size might not be best for the mother. The human
chromosome 14q21 region contains a cluster of imprinted
genes, some of which are maternally and some of which
are paternally expressed. Uniparental disomy (UPD) for
this region is recognized clinically. In the case of paternal
UPD, there are characteristic facial abnormalities, a small1Department of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA
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and bell-shaped thorax, abdominal-wall defects, and poly-
hydramnios, whereas maternal UPD is associated with pre-
natal and postnatal growth failure. Kagami et al. identiﬁed
several individuals who had clinical features of UPD14 but
had deletions or epigenetic changes in this region, and
they used them to deﬁne the region further. They found
that RTL1 has a critical role in the development of both
phenotypes and that over- and underexpression of the
gene makes a major contribution to the paternal UPD
and the maternal UPD phenotypes, respectively. At the
same time, Sekita et al. found that, in mice, Rtl1 is needed
for proper placental development and maintenance of
fetal capillaries at this interface. As in humans, tight regu-
lation of Rtl1 expression is necessary for proper develop-
ment. The complexity of this regulation is apparent from
the fact that RTL1 is a retrotransposon-derived gene that
is paternally expressed and regulated by a maternally
expressed microRNA. Not only does this work place RTL1
in a central role for the human phenotypes associated
with this region, but it also suggests a major role for the
gene in maintenance of the placenta and the evolution
of this organ in mammals.
M. Kagami et al. (2008). Nat. Genet. Published online
January 6, 2008. 10.1038/ng.2007.56; Y. Sekita et al. (2008).
Nat. Genet. Published online January 6, 2008. 10.1038/
ng.2007.51.Variation of Breast Cancer Risk among BRCA1/2
Carriers
The options given to women who are found to have
a mutation in either BRCA1 or BRCA2 are drastic and life
altering, namely prophylactic oophorectomy and/or mas-
tectomy. But exactly what is a mutation carrier’s risk of
developing breast or ovarian cancer? The literature on
this point can be overwhelming, and penetrance estimates
vary widely. Initial estimates calculated with high-risk,
multiple-case families suggested a breast cancer risk of
70%–80% in mutation carriers by age 70, but estimates
that used population-based ascertainment of breast cancer
cases suggested that the early estimates could be halved.
More comprehensive analyses put the estimate at some-
where in the middle, all of which makes counseling and
decision-making based on these estimates difﬁcult. The
risk estimates in the previous studies were made on groups
of mutation carriers considered as a whole. Begg et al. de-
cided to look at this problem in a slightly different way—
they wanted speciﬁcally to think about the variability in
risk between different breast cancer families. Even after
adjusting for speciﬁc characteristics of the proband, such
as their age at diagnosis, whether they had unilateral or260 The American Journal of Human Genetics 82, 259–260, Februarycontralateral breast cancer, and the location of the muta-
tion, they found strong evidence for between-family varia-
tion in risk of breast cancer in ﬁrst-degree relatives. In fact,
assuming a constant risk of breast cancer over most of
adult life, the variance they see implies that there may be
families in which the risk of breast cancer in mutation car-
riers is over 90% by age 70 and other families in which the
risk is similar to the general population’s risk for breast can-
cer. If not all ‘‘breast cancer families’’ are equal in terms of
breast cancer risk to mutation carriers, certainly our pene-
trance estimates for mutation carriers found in general
population screens are unlikely to be accurate. Now the
charge is to determine the additional genetic and environ-
mental factors that contribute to the residual cancer risk
and to ﬁnd ways of estimating family- and individual-spe-
ciﬁc mutation penetrance.
C.B. Begg et al. (2008). JAMA 299, 194–201.Correction of Fragile X Syndrome in Mice
The central question in fragile X syndrome (FXS) research
is this: How does the loss of a single protein lead to a disor-
der of neural development and cognitive impairment? The
hypothesis that has come closest to addressing this ques-
tion is the metabotropic glutamate receptor (mGluR) the-
ory of FXS, which suggests that loss of the fragile X mental
retardation protein, FMRP, leads to exaggerated signaling
through mGluRs, particularly mGluR5. Most of the evi-
dence for this idea is a result of pharmaceutical manipula-
tion of mGluRs, and the drugs utilized in those experi-
ments could have unintended effects. Do¨len et al. set out
to test this theory more directly through genetic reduc-
tions in the expression of mGluR5 in mice. They produced
Fmr1 knockout (KO) mice that expressed half the normal
amount of mGluR5, and they found that the reduction
in mGluR5 level rescued several phenotypes in the Fmr1
KO mice, including changes to the density of dendritic
spines, altered plasticity in the visual cortex, and increased
susceptibility to audiogenic seizures. Additionally, the au-
thors deﬁned for Fmr1 KO mice two new phenotypes—
rapid extinction of a learned behavioral response and ac-
celerated pubescent growth—that were also alleviated by
the reduction in mGluR5. This was not a complete ‘‘cure’’
for mouse FXS; at least one phenotype, macro-orchidism,
was not corrected by lowering of mGluR5. Not only do
these results lend further credence to the idea that some
components of the FXS phenotype are due to exaggerated
mGluR signaling, but they also provide fuel for the current
research into therapeutics—based on this idea—for FXS.
G. Do¨len et al. (2007). Neuron 56, 955–962. 10.1016/
j.neuron.2007.12.001.2008
